{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:51:43Z","timestamp":1794891103069,"version":"4.9.1"},"reference-count":97,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPPS"],"published-print":{"date-parts":[[2020,1,27]]},"abstract":"<jats:sec><jats:title\/><jats:p>Butyrylcholinesterase is a serine hydrolase that catalyzes the hydrolysis of esters in the body. Unlike its sister enzyme acetylcholinesterase, butyrylcholinesterase has a broad substrate scope and lower acetylcholine catalytic efficiency. The difference in tissue distribution and inhibitor sensitivity also points to its involvement external to cholinergic neurotransmission. Initial studies on butyrylcholinesterase showed that the inhibition of the enzyme led to the increment of brain acetylcholine levels. Further gene knockout studies suggested its involvement in the regulation of amyloid-beta, a brain pathogenic protein. Thus, it is an interesting target for neurological disorders such as Alzheimer\u2019s disease. The substrate scope of butyrylcholinesterase was recently found to include cocaine, as well as ghrelin, the \u201chunger hormone\u201d. These findings led to the development of recombinant butyrylcholinesterase mutants and viral gene therapy to combat cocaine addiction, along with in-depth studies on the significance of butyrylcholinesterase in obesity. It is observed that the pharmacological impact of butyrylcholinesterase increased in tandem with each reported finding. Not only is the enzyme now considered an important pharmacological target, it is also becoming an important tool to study the biological pathways in various diseases. Here, we review and summarize the biochemical properties of butyrylcholinesterase and its roles, as a cholinergic neurotransmitter, in various diseases, particularly neurodegenerative disorders.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389203720666191107094949","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T16:56:32Z","timestamp":1573232192000},"page":"99-109","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool"],"prefix":"10.2174","volume":"21","author":[{"given":"Zhe Ying","family":"Ha","sequence":"first","affiliation":[{"name":"School of Science, Monash University Malaysia Campus, Jalan Lagoon Selatan, Bandar Sunway, 47500, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintu","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), ITI Compound, Raebareli, 229010, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng Yoon","family":"Yeong","sequence":"additional","affiliation":[{"name":"School of Science, Monash University Malaysia Campus, Jalan Lagoon Selatan, Bandar Sunway, 47500, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1042\/bj2600625","volume":"260","author":"Chatonnet A.","year":"1989","unstructured":"Chatonnet A.; Lockridge O.; Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem J 1989,260(3),625-634","journal-title":"Biochem J"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1113\/jphysiol.1929.sp002598","volume":"68","author":"Dale H.H.","year":"1929","unstructured":"Dale H.H.; Dudley H.W.; The presence of histamine and acetylcholine in the spleen of the ox and the horse. J Physiol 1929,68(2),97-123","journal-title":"J Physiol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/S0021-9258(18)64073-6","volume":"236","author":"Wilson I.B.","year":"1961","unstructured":"Wilson I.B.; Harrison M.A.; Turnover number of acetyl-cholinesterase. J Biol Chem 1961,236(8),2292-2295","journal-title":"J Biol Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1042\/bj0370059","volume":"37","author":"Mendel B.","year":"1943","unstructured":"Mendel B.; Rudney H.; Studies on cholinesterase: 1. Cholinesterase and pseudo-cholinesterase. Biochem J 1943,37(1),59-63","journal-title":"Biochem J"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S0140-6736(52)92058-8","volume":"1","author":"Bourne J.G.","year":"1952","unstructured":"Bourne J.G.; Collier H.O.; Somers G.F.; Succinylcholine (succinoylcholine), muscle-relaxant of short action. Lancet 1952,1(6721),1225-1229","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/BF03005113","volume":"24","author":"Scholler K.L.","year":"1977","unstructured":"Scholler K.L.; Goedde H.W.; Benkmann H.G.; The use of serum cholinesterase in succinylcholine apnoea. Can Anaesth Soc J 1977,24(3),396-400","journal-title":"Can Anaesth Soc J"},{"key":"ref=7","first-page":"633","volume":"259","author":"Broomfield C.A.","year":"1991","unstructured":"Broomfield C.A.; Maxwell D.M.; Solana R.P.; Castro C.A.; Finger A.V.; Lenz D.E.; Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates. J Pharmacol Exp Ther 1991,259(2),633-638","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1016\/0006-2952(93)90228-O","volume":"45","author":"Raveh L.","year":"1993","unstructured":"Raveh L.; Grunwald J.; Marcus D.; Papier Y.; Cohen E.; Ashani Y.; Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem Pharmacol 1993,45(12),2465-2474","journal-title":"Biochem Pharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10646-007-0137-1","volume":"16","author":"Ahmed M.","year":"2007","unstructured":"Ahmed M.; Rocha J.B.; Mazzanti C.M.; Morsch A.L.; Cargnelutti D.; Corr\u00eaa M.; Loro V.; Morsch V.M.; Schetinger M.R.; Malathion, carbofuran and paraquat inhibit Bungarus sindanus (krait) venom acetylcholinesterase and human serum butyrylcholinesterase in vitro. Ecotoxicology 2007,16(4),363-369","journal-title":"Ecotoxicology"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF02815095","volume":"30","author":"G\u00f3mez-Ramos P.","year":"1996","unstructured":"G\u00f3mez-Ramos P.; Mor\u00e1n M.; Ultrastructural localization of butyrylcholinesterase in senile plaques in the brains of aged and Alzheimer disease patients. Mo Chem Neuropathol 1996,30(3),161-173","journal-title":"Mo Chem Neuropathol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0006-8993(86)91401-0","volume":"362","author":"Ruberg M.","year":"1986","unstructured":"Ruberg M.; Rieger F.; Villageois A.; Bonnet A.M.; Agid Y.; Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson\u2019s disease. Brain Res 1986,362(1),83-91","journal-title":"Brain Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/jcph.450","volume":"55","author":"Cohen-Barak O.","year":"2015","unstructured":"Cohen-Barak O.; Wildeman J.; van de Wetering J.; Hettinga J.; Schuilenga-Hut P.; Gross A.; Clark S.; Bassan M.; Gilgun-Sherki Y.; Mendzelevski B.; Spiegelstein O.; Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects. J Clin Pharmacol 2015,55(5),573-583","journal-title":"J Clin Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1210\/en.2016-1166","volume":"157","author":"Chen V.P.","year":"2016","unstructured":"Chen V.P.; Gao Y.; Geng L.; Stout M.B.; Jensen M.D.; Brimijoin S.; Butyrylcholinesterase deficiency promotes adipose tissue growth and hepatic lipid accumulation in male mice on high-fat diet. Endocrinology 2016,157(8),3086-3095","journal-title":"Endocrinology"},{"key":"ref=14","first-page":"54","volume":"28","author":"\u00c7oku\u011fra\u015f A.","year":"2003","unstructured":"\u00c7oku\u011fra\u015f A.; Butyrylcholinesterase: Structure and physiological importance. Turk J Biochem 2003,28(2),54-61","journal-title":"Turk J Biochem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1126\/science.1678899","volume":"253","author":"Sussman J.L.","year":"1991","unstructured":"Sussman J.L.; Harel M.; Frolow F.; Oefner C.; Goldman A.; Toker L.; Silman I.; Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991,253(5022),872-879","journal-title":"Science"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"41141","DOI":"10.1074\/jbc.M210241200","volume":"278","author":"Nicolet Y.","year":"2003","unstructured":"Nicolet Y.; Lockridge O.; Masson P.; Fontecilla-Camps J.C.; Nachon F.; Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 2003,278(42),41141-41147","journal-title":"J Biol Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"14642","DOI":"10.1021\/bi971425+","volume":"36","author":"Saxena A.","year":"1997","unstructured":"Saxena A.; Redman A.M.; Jiang X.; Lockridge O.; Doctor B.P.; Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 1997,36(48),14642-14651","journal-title":"Biochemistry"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"12074","DOI":"10.1021\/bi00096a018","volume":"32","author":"Radi\u0107 Z.","year":"1993","unstructured":"Radi\u0107 Z.; Pickering N.A.; Vellom D.C.; Camp S.; Taylor P.; Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. Biochemistry 1993,32(45),12074-12084","journal-title":"Biochemistry"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1021\/ja952232h","volume":"118","author":"Harel M.","year":"1996","unstructured":"Harel M.; Quinn D.; Nair H.; Silman I.; Sussman J.; The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase. J Am Chem Soc 1996,118(10),2340-2346","journal-title":"J Am Chem Soc"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0167-4838(99)00115-6","volume":"1433","author":"Masson P.","year":"1999","unstructured":"Masson P.; Xie W.; Froment M.T.; Levitsky V.; Fortier P.L.; Albaret C.; Lockridge O.; Interaction between the peripheral site residues of human butyrylcholinesterase, D70 and Y332, in binding and hydrolysis of substrates. Biochim Biophys Acta 1999,1433(1-2),281-293","journal-title":"Biochim Biophys Acta"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"10282","DOI":"10.1021\/jm300871x","volume":"55","author":"Cheung J.","year":"2012","unstructured":"Cheung J.; Rudolph M.J.; Burshteyn F.; Cassidy M.S.; Gary E.N.; Love J.; Franklin M.C.; Height J.J.; Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem 2012,55(22),10282-10286","journal-title":"J Med Chem"},{"key":"ref=22","first-page":"167","volume":"114","author":"Koelle G.B.","year":"1955","unstructured":"Koelle G.B.; Wagner H.; The histochemical identification of acetylcholinesterase in cholinergic, adrenergic and sensory neurons. J Pharmacol Exp Ther 1955,114(2),167-184","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/0041-0101(94)90416-2","volume":"32","author":"Jbilo O.","year":"1994","unstructured":"Jbilo O.; Bartels C.F.; Chatonnet A.; Toutant J.P.; Lockridge O.; Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon 1994,32(11),1445-1457","journal-title":"Toxicon"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0960327112468906","volume":"32","author":"Linhares A.G.","year":"2013","unstructured":"Linhares A.G.; Assis C.R.; Siqueira M.T.; Bezerra R.S.; Carvalho L.B.; Development of a method for extraction and assay of human erythrocyte acetylcholinesterase and pesticide inhibition. Hum Exp Toxicol 2013,32(8),837-845","journal-title":"Hum Exp Toxicol"},{"key":"ref=25","first-page":"232","volume":"15","author":"Freitas Leal J.K.","year":"2017","unstructured":"Freitas Leal J.K.; Adjobo-Hermans M.J.W.; Brock R.; Bosman G.J.C.G.M.; Acetylcholinesterase provides new insights into red blood cell ageing in vivo and in vitro. Blood Transfus 2017,15(3),232-238","journal-title":"Blood Transfus"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules22091499","volume":"22","author":"Saldanha C.","year":"2017","unstructured":"Saldanha C.; Human erythrocyte acetylcholinesterase in health and disease. Molecules 2017,22(9),1-10","journal-title":"Molecules"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1046\/j.1471-4159.2000.751320.x","volume":"75","author":"Li B.","year":"2000","unstructured":"Li B.; Stribley J.A.; Ticu A.; Xie W.; Schopfer L.M.; Hammond P.; Brimijoin S.; Hinrichs S.H.; Lockridge O.; Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J Neurochem 2000,75(3),1320-1331","journal-title":"J Neurochem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/0091-3057(78)90364-7","volume":"9","author":"Bartus R.T.","year":"1978","unstructured":"Bartus R.T.; Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav 1978,9(6),833-836","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0163-1047(86)80008-5","volume":"45","author":"Aigner T.G.","year":"1986","unstructured":"Aigner T.G.; Mishkin M.; The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav Neural Biol 1986,45(1),81-87","journal-title":"Behav Neural Biol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/09680519030090060401","volume":"9","author":"Czura C.J.","year":"2003","unstructured":"Czura C.J.; Friedman S.G.; Tracey K.J.; Neural inhibition of inflammation: the cholinergic anti-inflammatory pathway. J Endotoxin Res 2003,9(6),409-413","journal-title":"J Endotoxin Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"10180","DOI":"10.1523\/JNEUROSCI.3591-05.2005","volume":"25","author":"Liang X.","year":"2005","unstructured":"Liang X.; Wang Q.; Hand T.; Wu L.; Breyer R.M.; Montine T.J.; Andreasson K.; Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer\u2019s disease. J Neurosci 2005,25(44),10180-10187","journal-title":"J Neurosci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1742-2094-2-9","volume":"2","author":"Patel N.S.","year":"2005","unstructured":"Patel N.S.; Paris D.; Mathura V.; Quadros A.N.; Crawford F.C.; Mullan M.J.; Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer\u2019s disease. J Neuroinflammation 2005,2(1),9-19","journal-title":"J Neuroinflammation"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/archneur.63.8.1165","volume":"63","author":"Ramos E.M.","year":"2006","unstructured":"Ramos E.M.; Lin M.T.; Larson E.B.; Maezawa I.; Tseng L.H.; Edwards K.L.; Schellenberg G.D.; Hansen J.A.; Kukull W.A.; Jin L.W.; Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset alzheimer disease. Arch Neurol 2006,63(8),1165-1169","journal-title":"Arch Neurol"},{"key":"ref=34","first-page":"25","volume":"8","author":"Tobinick E.","year":"2006","unstructured":"Tobinick E.; Gross H.; Weinberger A.; Cohen H.; TNF-alpha modulation for treatment of Alzheimer\u2019s disease: a 6-month pilot study. MedGenMed 2006,8(2),25","journal-title":"MedGenMed"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1089\/jir.2013.0085","volume":"34","author":"Belkhelfa M.","year":"2014","unstructured":"Belkhelfa M.; Rafa H.; Medjeber O.; Arroul-Lammali A.; Behairi N.; Abada-Bendib M.; Makrelouf M.; Belarbi S.; Masmoudi A.N.; Tazir M.; Touil-Boukoffa C.; IFN-\u03b3 and TNF-\u03b1 are involved during Alzheimer disease progression and correlate with nitric oxide production: a study in Algerian patients. J Interferon Cytokine Res 2014,34(11),839-847","journal-title":"J Interferon Cytokine Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1750-1326-9-56","volume":"9","author":"Rossi S.","year":"2014","unstructured":"Rossi S.; Motta C.; Studer V.; Macchiarulo G.; Volpe E.; Barbieri F.; Ruocco G.; Buttari F.; Finardi A.; Mancino R.; Weiss S.; Battistini L.; Martino G.; Furlan R.; Drulovic J.; Centonze D.; Interleukin-1\u03b2 causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53. Mol Neurodegener 2014,9(1),56-67","journal-title":"Mol Neurodegener"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/ni0710-561","volume":"11","author":"Tracey K.J.","year":"2010","unstructured":"Tracey K.J.; Understanding immunity requires more than immunology. Nat Immunol 2010,11(7),561-564","journal-title":"Nat Immunol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/hmg\/9.9.1273","volume":"9","author":"Shapira M.","year":"2000","unstructured":"Shapira M.; Tur-Kaspa I.; Bosgraaf L.; Livni N.; Grant A.D.; Grisaru D.; Korner M.; Ebstein R.P.; Soreq H.; A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. Hum Mol Genet 2000,9(9),1273-1281","journal-title":"Hum Mol Genet"},{"key":"ref=39","first-page":"214","volume":"13","author":"Das N.U.","year":"2017","unstructured":"Das N.U.; Acetylcholinestrase and butyrylcholinesterase as possible markers of low- grade systemic inflammation. Med Sci Monit 2017,13(12),214-221","journal-title":"Med Sci Monit"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/BF00712843","volume":"10","author":"Donnelly R.J.","year":"1990","unstructured":"Donnelly R.J.; Friedhoff A.J.; Beer B.; Blume A.J.; Vitek M.P.; Interleukin-1 stimulates the beta-amyloid precursor protein promoter. Cell Mol Neurobiol 1990,10(4),485-495","journal-title":"Cell Mol Neurobiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/0197-4580(89)90077-8","volume":"10","author":"Blume A.J.","year":"1989","unstructured":"Blume A.J.; Vitek M.P.; Focusing on IL-1-promotion of \u03b2-amyloid precursor protein synthesis as an early event in Alzheimer\u2019s disease. Neurobiol Aging 1989,10(5),406-408","journal-title":"Neurobiol Aging"},{"key":"ref=42","first-page":"557","volume":"169","author":"Lanct\u00f4t K.L.","year":"2003","unstructured":"Lanct\u00f4t K.L.; Herrmann N.; Yau K.K.; Khan L.R.; Liu B.A.; LouLou, M.M.; Einarson, T.R. Efficacy and safety of cholinesterase inhibitors in Alzheimer\u2019s disease: a meta-analysis. CMAJ 2003,169(6),557-564","journal-title":"CMAJ"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1351\/pac199971112031","volume":"71","author":"Sugimoto H.","year":"1999","unstructured":"Sugimoto H.; Structure-activity relationships of acetylcholinesterase inhibitors: Donepezil hydrochloride for the treatment of Alzheimer\u2019s disease. Pure Appl Chem 1999,71(11),2031-2037","journal-title":"Pure Appl Chem"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S0149-2918(98)80127-6","volume":"20","author":"Polinsky R.J.","year":"1998","unstructured":"Polinsky R.J.; Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease. Clin Ther 1998,20(4),634-647","journal-title":"Clin Ther"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0006-3223(00)01101-X","volume":"49","author":"Coyle J.","year":"2001","unstructured":"Coyle J.; Kershaw P.; Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer\u2019s disease. Biol Psychiatry 2001,49(3),289-299","journal-title":"Biol Psychiatry"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/jama.289.2.210","volume":"289","author":"Trinh N.H.","year":"2003","unstructured":"Trinh N.H.; Hoblyn J.; Mohanty S.; Yaffe K.; Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003,289(2),210-216","journal-title":"JAMA"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-132690","volume":"41","author":"Tan C.C.","year":"2014","unstructured":"Tan C.C.; Yu J.T.; Wang H.F.; Tan M.S.; Meng X.F.; Wang C.; Jiang T.; Zhu X.C.; Tan L.; Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis. J Alzheimers Dis 2014,41(2),615-631","journal-title":"J Alzheimers Dis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.phrs.2003.11.017","volume":"50","author":"Giacobini E.","year":"2004","unstructured":"Giacobini E.; Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004,50(4),433-440","journal-title":"Pharmacol Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bbr.2011.07.035","volume":"225","author":"Furukawa-Hibi Y.","year":"2011","unstructured":"Furukawa-Hibi Y.; Alkam T.; Nitta A.; Matsuyama A.; Mizoguchi H.; Suzuki K.; Moussaoui S.; Yu Q.S.; Greig N.H.; Nagai T.; Yamada K.; Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-\u03b2 peptide in mice. Behav Brain Res 2011,225(1),222-229","journal-title":"Behav Brain Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/j.1471-4159.2006.04347.x","volume":"100","author":"Hartmann J.","year":"2007","unstructured":"Hartmann J.; Kiewert C.; Duysen E.G.; Lockridge O.; Greig N.H.; Klein J.; Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J Neurochem 2007,100(5),1421-1429","journal-title":"J Neurochem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.neuroscience.2015.04.039","volume":"298","author":"Reid G.A.","year":"2015","unstructured":"Reid G.A.; Darvesh S.; Butyrylcholinesterase-knockout reduces brain deposition of fibrillar \u03b2-amyloid in an Alzheimer mouse model. Neuroscience 2015,298(1),424-435","journal-title":"Neuroscience"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1021\/jm980459s","volume":"42","author":"Yu Q.","year":"1999","unstructured":"Yu Q.; Holloway H.W.; Utsuki T.; Brossi A.; Greig N.H.; Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer\u2019s disease. J Med Chem 1999,42(10),1855-1861","journal-title":"J Med Chem"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00702-008-0022-y","volume":"115","author":"Kamal M.A.","year":"2008","unstructured":"Kamal M.A.; Qu X.; Yu Q.S.; Tweedie D.; Holloway H.W.; Li Y.; Tan Y.; Greig N.H.; Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. J Neural Transm (Vienna) 2008,115(6),889-898","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=54","author":"Sugimoto H.","year":"2010","unstructured":"Sugimoto H.; Takahashi J.; Takahashi T.; Hijikuro I.; Indoline derivatives. US20110294850 2010"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ejmech.2018.01.007","volume":"145","author":"Chierrito T.P.C.","year":"2018","unstructured":"Chierrito T.P.C.; Pedersoli-Mantoani S.; Roca C.; Sebastian-P\u00e9rez V.; Mart\u00ednez-Gonzalez L.; P\u00e9rez D.I.; Perez C.; Canales A.; Ca\u00f1ada F.J.; Campillo N.E.; Carvalho I.; Martinez A.; Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem 2018,145(1),431-444","journal-title":"Eur J Med Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1021\/acs.jmedchem.7b01086","volume":"61","author":"Ko\u0161ak U.","year":"2018","unstructured":"Ko\u0161ak U.; Brus B.; Knez D.; \u017dakelj S.; Trontelj J.; Pi\u0161lar A.; \u0160ink R.; Juki\u010d M.; \u017divin M.; Podkowa A.; Nachon F.; Brazzolotto X.; Stojan J.; Kos J.; Coquelle N.; Sa\u0142at K.; Colletier J.P.; Gobec S.; The magic of crystal structure-based inhibitor optimization: development of a butyrylcholinesterase inhibitor with picomolar affinity and in vivo activity. J Med Chem 2018,61(1),119-139","journal-title":"J Med Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.bmc.2018.12.030","volume":"27","author":"de Andrade P.","year":"2019","unstructured":"de Andrade P.; Mantoani S.P.; Gon\u00e7alves Nunes P.S.; Magad\u00e1n C.R.; P\u00e9rez C.; Xavier D.J.; Hojo E.T.S.; Campillo N.E.; Mart\u00ednez A.; Carvalho I.; Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer\u2019s disease. Bioorg Med Chem 2019,27(6),931-943","journal-title":"Bioorg Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"8167","DOI":"10.1021\/jm501195e","volume":"57","author":"Brus B.","year":"2014","unstructured":"Brus B.; Ko\u0161ak U.; Turk S.; Pi\u0161lar A.; Coquelle N.; Kos J.; Stojan J.; Colletier J.P.; Gobec S.; Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. J Med Chem 2014,57(19),8167-8179","journal-title":"J Med Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.bioorg.2013.06.008","volume":"49","author":"Yoon Y.K.","year":"2013","unstructured":"Yoon Y.K.; Ali M.A.; Wei A.C.; Choon T.S.; Khaw K.Y.; Murugaiyah V.; Osman H.; Masand V.H.; Synthesis, characterization, and molecular docking analysis of novel benzimidazole derivatives as cholinesterase inhibitors. Bioorg Chem 2013,49(1),33-39","journal-title":"Bioorg Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s00044-016-1648-1","volume":"25","author":"Coban G.","year":"2016","unstructured":"Coban G.; Carlino L.; Tarikogullari A.H.; Parlar S.; Sar\u0131kaya G.; Alpt\u00fcz\u00fcn V.; Alpan A.S.; G\u00fcne\u015f H.S.; Erciyas E.; 1H-benzimidazole derivatives as butyrylcholinesterase inhibitors: synthesis and molecular modeling studies. Med Chem Res 2016,25(9),2005-2014","journal-title":"Med Chem Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejmech.2014.03.035","volume":"78","author":"Aslam S.","year":"2014","unstructured":"Aslam S.; Zaib S.; Ahmad M.; Gardiner J.M.; Ahmad A.; Hameed A.; Furtmann N.; G\u00fctschow M.; Bajorath J.; Iqbal J.; Novel structural hybrids of pyrazolobenzothiazines with benzimidazoles as cholinesterase inhibitors. Eur J Med Chem 2014,78(1),106-117","journal-title":"Eur J Med Chem"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1021\/acs.jmedchem.7b01760","volume":"61","author":"Dolles D.","year":"2018","unstructured":"Dolles D.; Hoffmann M.; Gunesch S.; Marinelli O.; M\u00f6ller J.; Santoni G.; Chatonnet A.; Lohse M.J.; Wittmann H.J.; Strasser A.; Nabissi M.; Maurice T.; Decker M.; Structure-activity relationships and computational investigations into the development of potent and balanced dual-acting butyrylcholinesterase inhibitors and human cannabinoid receptor 2 ligands with pro-cognitive in vivo profiles. J Med Chem 2018,61(4),1646-1663","journal-title":"J Med Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3233\/JAD-170164","volume":"58","author":"Macdonald I.R.","year":"2017","unstructured":"Macdonald I.R.; Maxwell S.P.; Reid G.A.; Cash M.K.; DeBay D.R.; Darvesh S.; Quantification of butyrylcholinesterase activity as a sensitive and specific biomarker of Alzheimer\u2019s disease. J Alzheimers Dis 2017,58(2),491-505","journal-title":"J Alzheimers Dis"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.trci.2017.01.005","volume":"3","author":"DeBay D.R.","year":"2017","unstructured":"DeBay D.R.; Reid G.A.; Pottie I.R.; Martin E.; Bowen C.V.; Darvesh S.; Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer\u2019s disease. Alzheimers Dement (N Y) 2017,3(2),166-176","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.bbr.2015.08.026","volume":"296","author":"Maurice T.","year":"2016","unstructured":"Maurice T.; Strehaiano M.; Sim\u00e9on N.; Bertrand C.; Chatonnet A.; Learning performances and vulnerability to amyloid toxicity in the butyrylcholinesterase knockout mouse. Behav Brain Res 2016,296(1),351-360","journal-title":"Behav Brain Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000113711","volume":"5","author":"Podoly E.","year":"2008","unstructured":"Podoly E.; Bruck T.; Diamant S.; Melamed-Book N.; Weiss A.; Huang Y.; Livnah O.; Langermann S.; Wilgus H.; Soreq H.; Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro. Neurodegener Dis 2008,5(3-4),232-236","journal-title":"Neurodegener Dis"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1073\/pnas.0602922103","volume":"103","author":"Diamant S.","year":"2006","unstructured":"Diamant S.; Podoly E.; Friedler A.; Ligumsky H.; Livnah O.; Soreq H.; Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA 2006,103(23),8628-8633","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/jmg.37.3.182","volume":"37","author":"McIlroy S.P.","year":"2000","unstructured":"McIlroy S.P.; Crawford V.L.; Dynan K.B.; McGleenon B.M.; Vahidassr M.D.; Lawson J.T.; Passmore A.P.; Butyrylcholinesterase K variant is genetically associated with late onset alzheimer\u2019s disease in Northern Ireland. J Med Genet 2000,37(3),182-185","journal-title":"J Med Genet"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3233\/JAD-160373","volume":"54","author":"De Beaumont L.","year":"2016","unstructured":"De Beaumont L.; Pelleieux S.; Lamarre-Th\u00e9roux L.; Dea D.; Poirier J.; Alzheimer\u2019s Disease Cooperative Study. Butyrylcholinesterase K and apolipoprotein E-\u025b4 reduce the age of onset of Alzheimer\u2019s disease, accelerate cognitive decline, and modulate donepezil response in mild cognitively impaired subjects. J Alzheimers Dis 2016,54(3),913-922","journal-title":"J Alzheimers Dis"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/NEN.0b013e31823cc7a6","volume":"71","author":"Darvesh S.","year":"2012","unstructured":"Darvesh S.; Cash M.K.; Reid G.A.; Martin E.; Mitnitski A.; Geula C.; Butyrylcholinesterase is associated with \u03b2-amyloid plaques in the transgenic APPSWE\/PSEN1dE9 mouse model of Alzheimer disease. J Neuropathol Exp Neurol 2012,71(1),2-14","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ana.24135","volume":"75","author":"Altmann A.","year":"2014","unstructured":"Altmann A.; Tian L.; Henderson V.W.; Greicius M.D.; Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol Alzheimer\u2019s Disease Neuroimaging Initiative Investigators2014,75(4),563-573","journal-title":"Ann Neurol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.trci.2015.07.001","volume":"1","author":"Lin K.A.","year":"2015","unstructured":"Lin K.A.; Choudhury K.R.; Rathakrishnan B.G.; Marks D.M.; Petrella J.R.; Doraiswamy P.M.; Alzheimer\u2019s Disease Neuroimaging Initiative. Marked gender differences in progression of mild cognitive impairment over 8 years. Alzheimers Dement (N Y) 2015,1(2),103-110","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=73","first-page":"1086","volume":"50","author":"Bartels C.F.","year":"1992","unstructured":"Bartels C.F.; Jensen F.S.; Lockridge O.; van der Spek A.F.; Rubinstein H.M.; Lubrano T.; La Du B.N.; DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 1992,50(5),1086-1103","journal-title":"Am J Hum Genet"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2147\/CIA.S137264","volume":"12","author":"Pongthanaracht N.","year":"2017","unstructured":"Pongthanaracht N.; Yanarojana S.; Pinthong D.; Unchern S.; Thithapandha A.; Assantachai P.; Supavilai P.; Association between butyrylcholinesterase K variant and mild cognitive impairment in the Thai community-dwelling patients. Clin Interv Aging 2017,12(1),897-901","journal-title":"Clin Interv Aging"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.neulet.2017.01.036","volume":"641","author":"Gabriel A.J.","year":"2017","unstructured":"Gabriel A.J.; Almeida M.R.; Ribeiro M.H.; Dur\u00e3es J.; T\u00e1buas-Pereira M.; Pinheiro A.C.; Pascoal R.; Santana I.; Baldeiras I.; Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer\u2019s disease patients. Neurosci Lett 2017,641(1),101-106","journal-title":"Neurosci Lett"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3233\/JAD-160562","volume":"56","author":"Sokolow S.","year":"2017","unstructured":"Sokolow S.; Li X.; Chen L.; Taylor K.D.; Rotter J.I.; Rissman R.A.; Aisen P.S.; Apostolova L.G.; Deleterious Effect of Butyrylcholinesterase K-variant in donepezil treatment of mild cognitive impairment. J Alzheimers Dis 2017,56(1),229-237","journal-title":"J Alzheimers Dis"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"S358","DOI":"10.1002\/mds.21677","volume":"22","author":"Caballol N.","year":"2007","unstructured":"Caballol N.; Mart\u00ed M.J.; Tolosa E.; Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 2007,22(17)(Suppl. 17),S358-S366","journal-title":"Mov Disord"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1080\/00207454.2017.1329203","volume":"127","author":"Josviak N.D.","year":"2017","unstructured":"Josviak N.D.; Batistela M.S.; Souza R.K.M.; Wegner N.R.; Bono G.F.; Sulzbach C.D.; Sim\u00e3o-Silva D.P.; Piovezan M.R.; Souza R.L.R.; Furtado-Alle L.; Plasma butyrylcholinesterase activity: a possible biomarker for differential diagnosis between Alzheimer\u2019s disease and dementia with Lewy bodies? Int J Neurosci 2017,127(12),1082-1086","journal-title":"Int J Neurosci"},{"key":"ref=79","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1524107","volume":"2017","author":"Dong M.X.","year":"2017","unstructured":"Dong M.X.; Xu X.M.; Hu L.; Liu Y.; Huang Y.J.; Wei Y.D.; Serum butyrylcholinesterase activity: A biomarker for Parkinson\u2019s disease and related dementia. BioMed Res Int 2017,2017(1)","journal-title":"BioMed Res Int"},{"key":"ref=80","first-page":"713","volume":"279","author":"Kamendulis L.M.","year":"1996","unstructured":"Kamendulis L.M.; Brzezinski M.R.; Pindel E.V.; Bosron W.F.; Dean R.A.; Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J Pharmacol Exp Ther 1996,279(2),713-717","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1006\/taap.1997.8188","volume":"145","author":"Mattes C.E.","year":"1997","unstructured":"Mattes C.E.; Lynch T.J.; Singh A.; Bradley R.M.; Kellaris P.A.; Brady R.O.; Dretchen K.L.; Therapeutic use of butyrylcholinesterase for cocaine intoxication. Toxicol Appl Pharmacol 1997,145(2),372-380","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cbi.2010.01.004","volume":"187","author":"Yang W.","year":"2010","unstructured":"Yang W.; Xue L.; Fang L.; Chen X.; Zhan C.G.; Characterization of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine. Chem Biol Interact 2010,187(1-3),148-152","journal-title":"Chem Biol Interact"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1038\/sj.npp.1301666","volume":"33","author":"Brimijoin S.","year":"2008","unstructured":"Brimijoin S.; Gao Y.; Anker J.J.; Gliddon L.A.; Lafleur D.; Shah R.; Zhao Q.; Singh M.; Carroll M.E.; A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 2008,33(11),2715-2725","journal-title":"Neuropsychopharmacology"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1369-1600.2011.00424.x","volume":"18","author":"Schindler C.W.","year":"2013","unstructured":"Schindler C.W.; Justinova Z.; Lafleur D.; Woods D.; Roschke V.; Hallak H.; Sklair-Tavron L.; Redhi G.H.; Yasar S.; Bergman J.; Goldberg S.R.; Modification of pharmacokinetic and abuse-related effects of cocaine by human-derived cocaine hydrolase in monkeys. Addict Biol 2013,18(1),30-39","journal-title":"Addict Biol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/JCP.0000000000000347","volume":"35","author":"Shram M.J.","year":"2015","unstructured":"Shram M.J.; Cohen-Barak O.; Chakraborty B.; Bassan M.; Schoedel K.A.; Hallak H.; Eyal E.; Weiss S.; Gilgun-Serki Y.; Sellers E.M.; Faulknor J.; Spiegelstein O.; Assessment of pharmacokinetic and pharmacodynamic interactions between albumin-fused mutated butyrylcholinesterase and intravenously administered cocaine in recreational cocaine users. J Clin Psychopharmacol 2015,35(4),396-405","journal-title":"J Clin Psychopharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.drugalcdep.2016.05.019","volume":"166","author":"Gilgun-Sherki Y.","year":"2016","unstructured":"Gilgun-Sherki Y.; Eliaz R.E.; McCann D.J.; Loupe P.S.; Eyal E.; Blatt K.; Cohen-Barak O.; Hallak H.; Chiang N.; Gyaw S.; Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence. Drug Alcohol Depend 2016,166(1),13-20","journal-title":"Drug Alcohol Depend"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1124\/jpet.115.228825","volume":"356","author":"Murthy V.","year":"2016","unstructured":"Murthy V.; Reyes S.; Geng L.; Gao Y.; Brimijoin S.; Cocaine hydrolase gene transfer demonstrates crdiac safety and efficacy against cocaine-induced QT prolongation in mice. J Pharmacol Exp Ther 2016,356(3),720-725","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/emj.2002.003251","volume":"21","author":"Taylor D.","year":"2004","unstructured":"Taylor D.; Parish D.; Thompson L.; Cavaliere M.; Cocaine induced prolongation of the QT interval. Emerg Med J 2004,21(2),252-253","journal-title":"Emerg Med J"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1208\/s12248-018-0214-9","volume":"20","author":"Chen X.","year":"2018","unstructured":"Chen X.; Deng J.; Cui W.; Hou S.; Zhang J.; Zheng X.; Ding X.; Wei H.; Zhou Z.; Kim K.; Zhan C.G.; Zheng F.; Development of Fc-fused cocaine hydrolase for cocaine addiction treatment: Catalytic and pharmacokinetic properties. AAPS J 2018,20(3),53","journal-title":"AAPS J"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/0140-6736(91)91164-P","volume":"337","author":"McKeigue P.M.","year":"1991","unstructured":"McKeigue P.M.; Shah B.; Marmot M.G.; Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991,337(8738),382-386","journal-title":"Lancet"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.287.18.2414","volume":"287","author":"Ludwig D.S.","year":"2002","unstructured":"Ludwig D.S.; The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 2002,287(18),2414-2423","journal-title":"JAMA"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1152\/physrev.00012.2004","volume":"85","author":"Kojima M.","year":"2005","unstructured":"Kojima M.; Kangawa K.; Ghrelin: structure and function. Physiol Rev 2005,85(2),495-522","journal-title":"Physiol Rev"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10571-017-0523-z","volume":"38","author":"Brimijoin S.","year":"2018","unstructured":"Brimijoin S.; Tye S.; Favourable impact on stress-related behaviors by modulating plasma butyrylcholinesterase. Cell Mol Neurobiol 2018,38(1),7-12","journal-title":"Cell Mol Neurobiol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ygcen.2015.05.017","volume":"224","author":"Schopfer L.M.","year":"2015","unstructured":"Schopfer L.M.; Lockridge O.; Brimijoin S.; Pure human butyrylcholinesterase hydrolyzes octanoyl ghrelin to desacyl ghrelin. Gen Comp Endocrinol 2015,224(1),61-68","journal-title":"Gen Comp Endocrinol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cbi.2008.03.009","volume":"175","author":"Li B.","year":"2008","unstructured":"Li B.; Duysen E.G.; Lockridge O.; The butyrylcholinesterase knockout mouse is obese on a high-fat diet. Chem Biol Interact 2008,175(1-3),88-91","journal-title":"Chem Biol Interact"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12291-014-0443-3","volume":"30","author":"Tangvarasittichai S.","year":"2015","unstructured":"Tangvarasittichai S.; Pongthaisong S.; Meemark S.; Tangvarasittichai O.; Abdominal obesity associated with elevated serum butyrylcholinesterase activity, insulin resistance and reduced high density lipoprotein-cholesterol levels. Indian J Clin Biochem 2015,30(3),275-280","journal-title":"Indian J Clin Biochem"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2174\/1567205012666150710115506","volume":"12","author":"Nuzzo D.","year":"2015","unstructured":"Nuzzo D.; Picone P.; Baldassano S.; Caruana L.; Messina E.; Marino Gammazza A.; Cappello F.; Mul\u00e8 F.; Di Carlo M.; Insulin resistance as common molecular denominator linking obesity to Alzheimer\u2019s disease. Curr Alzheimer Res 2015,12(8),723-735","journal-title":"Curr Alzheimer Res"}],"container-title":["Current Protein &amp; Peptide Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/176467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T20:28:30Z","timestamp":1611865710000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/176467\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,27]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389203720666191107094949","relation":{},"ISSN":["1389-2037"],"issn-type":[{"value":"1389-2037","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}